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Objectives: To explore the cost-effectiveness of clopidogrel as secondary preven-
tion in patients with a recent ischemic stroke (IS), or established peripheral arte-
rial disease (PAD) compared with aspirin in China. MethOds: A discrete event 
simulation was developed to evaluate the economic implications of secondary 
prevention with clopidogrel or aspirin, which are indicated for a patient with a 
recent MI, recent IS or established PAD. All available evidences were derived from 
clinical studies. Costs from Chinese health care perspective in 2013 US dollars 
and quality-adjusted life years (QALYs) were projected over a patient’s lifetime. 
Uncertainties were addressed using sensitivity analyses. Results: Compared with 
aspirin, clopidogrel yielded marginal life expectancy by 0.46 and 0.21 QALYs at 
an incremental cost-effectiveness ratio of $5,246 and $9,890 per QALY in patients 
with a recent IS and PAD, respectively. One-way sensitivity analyses showed evalu-
ation for patients with PAD and a recent IS was robust except the parameter of 
patient age. For the willingness to pay for $19,877 per QALY gained, clopidogrel 
intervention had a probability of 90% and 68% of being cost-effective for IS and 
PAD subgroups in comparison with aspirin, respectively. cOnclusiOns: The 
analysis suggests that clopidogrel for the secondary prevention is cost effective for 
patients with either PAD or a recent IS in the Chinese setting in comparison with 
aspirin.
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Objectives: Riociguat is the first product proven to improve health status in CTEPH 
patients. The objective of this study is to evaluate the cost-effectiveness of riociguat 
for patients with inoperable CTEPH or post-operative recurrent/persistent CTEPH in 
Turkey. MethOds: A Markov model taking transitions of patients between func-
tional classes and death state as core was adapted to Turkish setting. Turkish payer’s 
perspective was taken and time-horizon was set as patient’s lifetime (maximum 30 
years) broken into four-month cycles. Riociguat was compared to placebo and com-
mon off-label treatments within the model. Essential clinical inputs were derived 
from CHEST-1 and CHEST-2 trials and local resource-utilization data were conducted 
through an expert panel. The incremental cost-effectiveness ratios (ICER) were calcu-
lated per life-years (LYs) gained and sensitivity of the results was analyzed for all com-
parators and placebo in terms of key inputs. All costs were calculated in Turkish Liras 
(TL) and converted to USD using TL/USD currency rate as 2.1 (mid-2014). Results: 
Total cost of riociguat-treated patients is 1,558, 7,342 and 59,706 USD higher compared 
to bosentan, ambrisentan and sildenafil respectively and 74,227 USD lower compared 
to iloprost. Besides, riociguat is associated with increments of 1.0034, 1.0878, 1.8174 
and 1.8872 LYs compared to bosentan, ambrisentan, iloprost, sildenafil and placebo 
respectively. The ICER of riociguat per LYs gained compared to bosentan, ambrisentan, 
sildenafil and placebo were determined as 1,553 USD, 6,750 USD, 31,638 USD and 
39,553 USD correspondingly. Model is sensitive only to the changes in “the starting 
age of the disease”, yet not to an extent to affect the final results. cOnclusiOns: 
Riociguat is cost-effective for CTEPH treatment compared to bosentan, ambrisen-
tan, sildenafil and placebo with ICER values below the willingness-to-pay thresh-
old (3-times GDP per capita ─ 32,346 USD) for Turkey. Furthermore, riociguat is 
pharmacoeconomically dominant to iloprost with lower costs and higher clinical 
effectiveness.
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Objectives: The objective of this study was to compare the efficacy, complica-
tions, and costs associated with urokinase versus alteplase for the catheter-directed 
treatment of acute peripheral artery disease (APAD). MethOds: The cost-effec-
tiveness of catheter directed thrombolysis (CDT) with urokinase and alteplase for 
the treatment of APAD was compared using decision analysis. A literature-based 
decision model to evaluate cost-effectiveness was constructed. Successful treat-
ment outcomes were defined as clot lysis with a subsequent 30-day survival post-
treatment. Direct medical costs were assessed from the payer perspective in the 
Kazakhstan and analyzed using sensitivity analyses. A Monte Carlo analysis with 
1000 patients was performed to obtain mean and incremental cost-effectiveness 
ratios (ICERs). Results: The mean cost-effectiveness ratio was $148 463 per treat-
ment success for CDT with urokinase and $220 052 for CDT with alteplase. The ICER 
for alteplase relative to urokinase was $211 573 per additional CDT treatment suc-
cess. Approximately 75% of simulated cases indicated that alteplase was associated 
with increased costs and increased treatment success compared with urokinase. 
Also, when using alteplase higher risk of bleeding than with urokinase, this com-
plication is a major factor limiting the using of CDT. Results of a post hoc sensitivity 
analysis indicated that dominance decreased to approximately 10% of cases only 
under the most strict criteria. cOnclusiOns: Decision analysis found an ICER of 
$211 573 per additional CDT treatment success for alteplase relative to urokinase in 
the treatment of APAD from the perspective of the payer in the Kazakhstan. In about 
75% of cases resulting from a Monte Carlo simulation, alteplase was associated 
with increased costs and slightly increased CDT treatment success compared with 
urokinase, although this finding was sensitive to the distributional assumptions 
made concerning certain costs in the model.
were extracted from the RELY trial; utilities were derived from the literature. Costs 
for medications and procedures were obtained from official government databases, 
all costs were in 2014 Colombian pesos (1 USD = 2000.33 COP). Annual discount 
rate was 5% and we used a life time horizon (close to 20 years, on average). Cost-
effectiveness threshold was 3 times per capita GDP (around USD 22,500). Results: 
Compared with warfarin, patients treated with dabigatran 150 and 110 mg gained, 
on average 0.37 and 0.23 life-years, respectively, or 0.38 and 0.25 QALYs. The ICER for 
dabigatran 150 mg was USD 13,248 per QALY, and for dabigatran 110 mg was 23,621 
per QALY. cOnclusiOns: Dabigatran 150, compared with warfarin, the standard 
therapy, is cost-effective for ambulatory treatment of patients with non valvular AF. 
Dabigatran 110 ICER is discretely over the threshold (around 1000 USD).
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Objectives: To determine the economic value of dabigatran for stroke preven-
tion in atrial fibrillation (SPAF) compared to other reimbursed oral anticoagulants 
warfarin, rivaroxaban and apixaban from a perspective of Mexican public institu-
tions. MethOds: A Markov disease model with three month cycles length was 
developed. A number of clinically relevant events, including acute thromboembolic 
and bleeding events, as well as long-term consequences such as stroke, intracranial 
hemorrhage and acute myocardial infarction, were followed in the model within 
the lifetime horizon (mean 10 years from diagnosis for Mexican patients). Identical 
hypothetical cohorts of patients entered the model, following a disease background 
of atrial fibrillation (2500 simulations per treatment arm). Published results of head 
to head clinical trials or relative efficacy derived in network meta-analysis and indi-
rect comparisons were used to populate the model. Public institutional direct medi-
cal costs (2014 purchases and price tabulators) where retrieved to adopt the national 
health system perspective. Model outputs included total costs, event rates and 
life-years gained. Results: Mean life-years saved for dabigatran, apixaban, rivar-
oxaban and warfarin were 69.435, 69.219, 68.737 and 68.373 respectively. Estimated 
cost of treatment for dabigatran, warfarin, rivaroxaban and apixaban were 110,942 
USD, 108,757 USD, 124,718 USD and 112,373 USD, respectively. ICER showed that 
dabigatran is a cost-saving alternative versus rivaroxaban and apixaban, and a 
cost-effective one versus warfarin (defined by a one GDP per capita threshold in the 
country). These results where robust to changes in discount rates. cOnclusiOns: 
From a perspective of Mexican public institutions, the treatment with dabigatran 
was found to be cost-effective when compared with warfarin and economically 
dominant versus rivaroxaban and apixaban as it resulted in highest projected life 
years gained at lower costs.
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Objectives: Some high-risk CHD patients have poor outcomes with statin therapy 
and need to use combination regimens. The combination regimens have not been 
widely found in cost-effectiveness study. Therefore, this study aimed to analyze the 
cost-effectiveness of using Simvastatin, Atorvastatin, and Atorvastatin-Ezetimibe 
combination among high-risk CHD outpatients. MethOds: A cross-sectional ret-
rospective study for 12 months (April 1, 2013 to April 1, 2014) in high-risk CHD out-
patients was performed at the Chandrubeksa Hospital Medical Department of the 
Royal Thai Air Force, Nakhon Pathom, Thailand. The incremental cost-effectiveness 
ratio (ICER) was determined for cost-effectiveness analysis. The direct medical costs 
were computed by micro-costing method (Reference price in 2014). The effective-
ness outcomes were the percentage differences in LDL-C reduction and the pro-
portion of patients achieving treatment goals (Standard goal (LDL-C < 100 mg/dL) 
and Aggressive goal (LDL-C < 70 mg/dL)). The cost-effectiveness was concerned on 
the provider perspective. Results: There were differences of the direct medical 
costs between three groups (median ± IQR: 517 ± 149.7, 3,910.4 ± 3,326.5, 13,733.7 
± 3,350.0; p 0.0001, respectively). Simvastatin regimen had the lowest percentage 
differences in LDL-C reduction when compared to other groups (mean ± SD ; -20.1 
± 30.1, -28.3 ± 24.2, -38.1 ± 17.1; p 0.0001, respectively). Atorvastatin regimen provide 
the best cost-effectiveness (ICER = 346.4 THB) by using the proportion achieved 
standard treatment goal, while Atorvastatin-Ezetimibe combination was dominated. 
In the case of the aggressive treatment goal showed that Atorvastatin-Ezetimibe 
combination regimens provided the most cost-effectiveness (ICER 437.7 THB and 
1,189.8 THB, respectively). cOnclusiOns: Comparison treatment with Simvastatin, 
Atorvastatin and Atorvastatin-Ezetimibe combination among high-risk CHD out-
patients showed that Atorvastatin was more effectiveness and less costly than 
Atorvastatin-Ezetimibe combination in term of standard treatment goal. While 
Atorvastatin-Ezetimibe combination was an interesting option when aggressive 
treatment goal was used.
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